HERCULES, Calif. & SAN DIEGO--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
Most scientific studies rely on analysis of bulk tissue samples. These samples are usually composed of multiple cell types with varying functions. Gene expression data is averaged across cells, making it difficult to identify differences between cells and to understand the role of cell variation. Single-cell sequencing addresses those challenges and provides deeper insight into cell function, disease progression and therapeutic response. These data can be important in studies of neurological tissues, for example, which are known to have hundreds of specialized cell types.
Using Bio-Rad’s best-in-class droplet partitioning technology and Illumina’s leading NGS technologies, the new solution is optimized to isolate and barcode single cells for downstream sequencing. Data analysis is conducted via BaseSpace, Illumina’s cloud-based genomics computing environment. The solution will be scalable to isolate significantly larger numbers of single cells compared to commercially available solutions today, in just a few minutes at a cost-effective price.
“We welcome the opportunity to collaborate with Illumina, the global leader in NGS technologies, to develop this long-awaited platform for single-cell genomics,” said Annette Tumolo, Bio-Rad Executive Vice President and General Manager, Digital Biology Center. “Through this partnership, we will deliver a seamless, yet scalable solution for single-cell gene expression analysis.”
“By collaborating with Bio-Rad, both companies will be able to serve the significant market for single-cell NGS, enabling scientists to make groundbreaking advances in gene expression and beyond,” said Christian Henry, Executive Vice President and Chief Commercial Officer at Illumina. “Bio-Rad is recognized for delivering trusted, high-quality products in a market with increasingly stringent regulations and standards. We look forward to working with them on such an important endeavor.”
The companies expect to launch the solution in late 2016 or early 2017.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina assumes no obligation to update any forward-looking statements after the date of this release.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, problems we may encounter with our supply chain and product quality issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
